# Metacrine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/metacrine

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.metacrine.com
- Total disclosed funding: $99M
- Latest round: Series C (Jun 5, 2018)
- Investors on record: 13

## About

Metacrine, Inc. is a biopharmaceutical company based in the US focused on developing innovative therapeutic solutions for patients with liver and gastrointestinal diseases.Founded in 2014 by Ronald Evans, Metacrine, Inc. specializes in biopharmaceuticals. Headquartered in San Diego, California, the company raised USD 85.02 mn in its IPO in September 2020, successfully selling 6.54 million shares at USD 13 per share. This round was pivotal in expanding its clinical development pipeline, particularly targeting the FXR program for NASH and gastrointestinal diseases.Metacrine, Inc. aims to develop advanced therapeutics addressing unmet medical needs in liver and gastrointestinal disorders. Their primary focus is on innovative drug development that targets specific pathways in these diseases, enhancing treatment efficacy and patient outcomes.For the year 2021, Metacrine, Inc. reported an EBITDA of -USD 60.11 mn, indicating the company is still in the investment phase of its development cycle, focusing on R&D and clinical trials rather than immediate profitability.Metacrine, Inc. is strategically positioning itself for growth with plans to enhance its clinical development pipeline, utilizing the USD 85.02 mn raised in its IPO to advance the FXR program focused on NASH and gastrointestinal diseases. The funds will support ongoing clinical trials and the potential introduction of new therapeutics in the next few years, aiming for broader market presence in North America and Europe by 2023.

## Funding rounds

- Series C, Jun 5, 2018, $65M — ARCH Venture Partners, New Enterprise Associates, Polaris Partners, Venrock, Alexandria Venture Investments, Vivo Capital, Invus [DUP], Lilly Asia Ventures, ArrowMark Partners, VenBio, Deerfield Management, Franklin Templeton
- Series B, Dec 7, 2017, $22M — ARCH Venture Partners, New Enterprise Associates, Polaris Partners, Alexandria Venture Investments, VenBio
- Series A, Oct 6, 2015, $5.3M — ARCH Venture Partners, Polaris Partners, VenBio, EcoR1 Capital
- Series A, Apr 13, 2015, $6.8M — ARCH Venture Partners, Polaris Partners, VenBio, EcoR1 Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A, Series B, Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B, Series C
- Venrock (https://capitalatlas.ai/funds/venrock) — Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Invus [DUP] — Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series C
- ArrowMark Partners — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series C